Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

[1]  P. Tsichlis,et al.  Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Kretzner,et al.  Novel expression patterns of the myc/max/mad transcription factor network in developing murine prostate gland. , 2001, The Journal of urology.

[3]  P. Humphrey,et al.  A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[5]  Rosalie C Sears,et al.  Signaling Networks That Link Cell Proliferation and Cell Fate* , 2002, The Journal of Biological Chemistry.

[6]  R. Matusik,et al.  Erratum: Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: A model for prostate cancer (Laboratory Iinvestigation (March 1998) 78 (319-333)) , 1998 .

[7]  I. Fidler,et al.  Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  G. Prendergast,et al.  Mechanisms of apoptosis by c-Myc , 1999, Oncogene.

[9]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[10]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[11]  R. Matusik,et al.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. , 2000, Endocrinology.

[12]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[13]  E. Bergstralh,et al.  Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ‐confined prostate cancer , 2002, Genes, chromosomes & cancer.

[14]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[15]  D. Felsher,et al.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. , 2003, Blood.

[16]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[17]  E. Lander,et al.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Bostwick,et al.  Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.

[19]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[20]  Yun-Fai Chris Lau,et al.  Unopposed c‐MYC expression in benign prostatic epithelium causes a cancer phenotype , 2005, The Prostate.

[21]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[22]  G. Evan,et al.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.

[23]  E. Prochownik,et al.  MYC oncogenes and human neoplastic disease , 1999, Oncogene.

[24]  A Ma,et al.  E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. , 1991, Oncogene.

[25]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[26]  A. Iavarone,et al.  Id proteins at the cross-road of development and cancer , 2001, Oncogene.

[27]  Lene Rask,et al.  Astroglial c-Myc Overexpression Predisposes Mice to Primary Malignant Gliomas* , 2003, The Journal of Biological Chemistry.

[28]  A. Gartel,et al.  Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. , 2003, Experimental cell research.

[29]  D. Bostwick,et al.  Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[30]  M. Vaarala,et al.  The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: Detection of mutated TMPRSS2 form in a case of aggressive disease , 2001, International journal of cancer.

[31]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[32]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[33]  O. Kallioniemi,et al.  Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. , 2000, Cancer research.

[34]  R. Cardiff,et al.  Nkx 3 . 1 Mutant Mice Recapitulate Early Stages of Prostate Carcinogenesis 1 , 2002 .

[35]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Visakorpi.  Molecular genetics of prostate cancer. , 1999, Annales chirurgiae et gynaecologiae.

[37]  P. Roy-Burman,et al.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.

[38]  P. Chaurand,et al.  A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. , 2001, Cancer research.

[39]  B. Amati,et al.  Myc and the cell cycle. , 1998, Frontiers in bioscience : a journal and virtual library.

[40]  R. Hynes,et al.  Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Tapio Visakorpi,et al.  Molecular genetics of prostate cancer , 2001, Urology.

[43]  Peter A. Humphrey,et al.  Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia , 2002, Molecular and Cellular Biology.

[44]  R. Matusik,et al.  Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[45]  D. Hanahan,et al.  Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. , 1995, Oncogene.

[46]  R. Weinberg,et al.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. , 2003, Cancer cell.

[47]  M. Rubin,et al.  Prostatic neoplasia in transgenic mice with prostate‐directed overexpression of the c‐myc oncoprotein , 2000, The Prostate.

[48]  J. Ward,et al.  Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. , 1996, Cancer research.

[49]  W. Hahn,et al.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.

[50]  Andreas Rosenwald,et al.  Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol , 2001, Genome Biology.

[51]  R. T. Curtis,et al.  A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. , 1997, Genomics.

[52]  R. Reiter,et al.  Role of prostate stem cell antigen in prostate cancer research , 2002, Current opinion in urology.

[53]  R L Vessella,et al.  Differential expression of osteonectin/SPARC during human prostate cancer progression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[56]  M. Augustus,et al.  Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. , 1997, Cancer research.

[57]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[58]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[59]  C. Perez-stable,et al.  Prostate cancer progression, metastasis, and gene expression in transgenic mice. , 1997, Cancer research.

[60]  Anton Berns,et al.  Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging , 1991, Cell.